Search clinical trials for: Nivolumab Ipilimumab

Total 1954 results

Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Lung Cancer

Italy, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Recruiting

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Taiwan
Ontario Clinical Oncology Group (OCOG)
Bristol-Myers Squibb

Active, not recruiting

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)

Metastatic Renal Cell Carcinoma

Canada, Australia
Bristol-Myers Squibb

Completed

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914)

Carcinoma, Renal Cell

United States, Italy, Brazil, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, France, Germany, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, Singapore, Spain, Switzerland, Turkey, United...
Jason J. Luke, MD
Array BioPharma

Active, not recruiting

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Baptist Health South Florida
Bristol-Myers Squibb; NovoCure Ltd.

Terminated

Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

Recurrent Glioblastoma

United States
Universitair Ziekenhuis Brussel

Not yet recruiting

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI)

Recurrent Glioblastoma

Belgium
Italian Network for Tumor Biotherapy Foundation
Bristol-Myers Squibb; Astex Pharmaceuticals, Inc.

Not yet recruiting

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)

Melanoma | Non Small Cell Lung Cancer

Italy
Universitätsklinikum Köln
ZKS Köln

Withdrawn

Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients (CERAD-IMMUNE)

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE)

Colorectal Cancer Metastatic | MSI-H Colorectal Cancer

France
Italian Network for Tumor Biotherapy Foundation
Bristol-Myers Squibb

Unknown

A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (NIBIT-M2)

Brain Metastases

Italy
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb; Cancer Research Institute, New York City

Completed

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

Advanced Metastatic Cancer | Advanced Prostate Cancer

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT)

Stage III/IV Melanoma

France
University of Pittsburgh
Bristol-Myers Squibb

Withdrawn

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

Melanoma

United States
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA)

Malignant Melanoma Stage III

United States, Netherlands, Australia
Bristol-Myers Squibb

Completed

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

Melanoma

United States
Lung Cancer Group Cologne
Bristol-Myers Squibb

Completed

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

Carcinoma, Non-Small-Cell Lung | Carcinoma, Small Cell Lung

Germany
Michael B. Atkins, MD
Bristol-Myers Squibb; Hoosier Cancer Research Network

Active, not recruiting

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

United States
University of Rochester

Active, not recruiting

Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

Sarcoma

United States
University College, London
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Prostate Cancer

United Kingdom
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Metastatic Melanoma

United States
Intergroupe Francophone de Cancerologie Thoracique

Completed

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (MAPS2)

Mesothelioma

France
University Hospital Heidelberg

Unknown

Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP)

Cancer of Unknown Primary Site

Germany
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
ARCAGY/ GINECO GROUP
Bristol-Myers Squibb

Active, not recruiting

COL Immunotherapy Before Radiochimio + Ipilimumab (COLIBRI)

Cervix Cancer

France
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
NYU Langone Health

Terminated

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Rennes University Hospital

Completed

Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients (eNERGY)

Advanced Non Small Cell Lung Cancer

France
Pfizer
Bristol-Myers Squibb

Completed

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

MSS | RAS-mutant Colorectal Cancer

United States, Spain, Belgium, United Kingdom, Netherlands
European Organisation for Research and Treatment...

Active, not recruiting

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence (VESTIGE)

Gastric and Esophagogastric Junction Adenocarcinoma

United Kingdom, Italy, France, Spain, Germany, Czechia, Israel, Norway, Poland
AIO-Studien-gGmbH
Bristol-Myers Squibb

Active, not recruiting

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma (TITAN-TCC)

Transitional Cell Carcinoma | Metastatic Cancer | Advanced Cancer

Germany, Austria
Universitair Ziekenhuis Brussel

Completed

A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases (ipniv)

Stage IV Skin Melanoma | Stage IIIC Skin Melanoma

Belgium
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb

Completed

Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

Melanoma

United States
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (TITAN-RCC)

Carcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma

Spain, France, Italy, Germany, United Kingdom, Belgium, Czechia, Austria
Yale University
AstraZeneca

Withdrawn

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Malignant Melanoma
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb; UConn Health; Adaptive Biotechnologies; MedGenome

Completed

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Melanoma | Bladder Cancer

United States
European Organisation for Research and Treatment...

Active, not recruiting

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)

Stage IV Melanoma | Unresectable Stage III Melanoma

France, Denmark, Spain, Finland, Italy, Germany, Poland, United Kingdom, Netherlands
Swiss Group for Clinical Cancer Research

Active, not recruiting

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

Switzerland
Yale University
Bristol-Myers Squibb

Completed

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

Carcinoma, Non-Small-Cell Lung

United States
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (Indi-Blade)

Bladder Cancer | Urothelial Carcinoma

Netherlands
Institut Claudius Regaud

Terminated

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Melanoma

France
Fondazione Ricerca Traslazionale
Clinical Research Technology S.r.l.

Unknown

An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (SQUINT)

Squamous-Cell Lung Cancer

Italy
University of Zurich

Recruiting

Intrathecal Double Checkpoint Inhibition (IT-IO)

Melanoma Stage IV | Leptomeningeal Metastasis | Non-small Cell Lung Cancer Stage IV

Switzerland
Universitätsklinikum Hamburg-Eppendorf
Charite University, Berlin, Germany; University Hospital, Essen; Westpfalz-Clinical...

Active, not recruiting

Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy (IMSTAR-HN)

Head and Neck Cancer

Germany
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Sweden, Swit... and more
Universita di Verona

Not yet recruiting

Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR)

HIV | HBV | Long COVID | NSCLC Stage IV | HCV

Italy
Yale University
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

Small Cell Lung Cancer

United States
Gritstone bio, Inc.
Bristol-Myers Squibb

Completed

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Colorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Shared Neoantigen-Positive Solid Tumors

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648)

Various Advanced Cancer

United States, Japan, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, France, Hong Kong, Italy, Korea, Republic of, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Singapore, Spain, ... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)

Melanoma

Argentina, United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Norway, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom

Search clinical trials for: Nivolumab Ipilimumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations